GNMX

Aevi Genomic Medicine, Inc.
GNMX

Overview Fund Activity
Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

49 hedge funds and large institutions have $12.6M invested in Aevi Genomic Medicine, Inc. in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 7 closing their positions.

Holders
49
Holders Change
-2
Holders Change %
-3.92%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
12
Reduced
14
Closed
7
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
+$68K

Top Buyers

1
BBA
1
Baker Bros. Advisors
New York
$5.73M
2
Wells Fargo
2
Wells Fargo
California
$165K
3
PAM
3
Panagora Asset Management
Massachusetts
$74K
4
NCMW
4
Northern Capital Management (Wisconsin)
Wisconsin
$192K
5
VF
5
Virtu Financial
New York
$45K

Top Sellers

1
Goldman Sachs
1
Goldman Sachs
New York
$111K
2
ECM
2
Element Capital Management
New York
$0
3
LP
3
LMR Partners
United Kingdom
$0
4
PP
4
Paloma Partners
Connecticut
$0
5
Morgan Stanley
5
Morgan Stanley
New York
$9K
Name Market Value Shares Shares
Change 		Shares
Change %
TRCT
51
Tower Research Capital (TRC)
New York
– – -10,365 Closed
Two Sigma Advisers
52
Two Sigma Advisers
New York
– – -10,100 Closed
KF
53
Krilogy Financial
Missouri
– – -300 Closed
Deutsche Bank
54
Deutsche Bank
Germany
$0 69 -1 -1%
Group One Trading
55
Group One Trading
Illinois
– – – –
Simplex Trading
56
Simplex Trading
Illinois
$0 229 +229 New
PCM
57
Prelude Capital Management
New York
$0 300 +300 New
1 2
3